Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.

Active as of 2024-12-19

Generated Narrative: Citation 179625

version: 8; Last updated: 2024-11-22 19:20:23+0000

Profile: JournalArticleCitation

url: Citation 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/179625, https://pubmed.ncbi.nlm.nih.gov/22502942, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.5

version: 2.0.0-ballot

title: 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

-CodeValue[x]
*Citation Classification Type fevir-platform-use: FEvIR Platform UseMedline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2012-12-07

lastReviewDate: 2022-03-10

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Received

period: ?? --> 2012-02-03

statusDate

activity: PubMed Pubstatus of Accepted

period: ?? --> 2012-03-23

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2012-04-17 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2012-04-17 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2012-12-12 06:00:00+0000

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/22502942, https://doi.org/10.1016/j.eururo.2012.03.053, pii/S0302-2838(12)00425-3

Titles

-TypeLanguageText
*Primary titleEnglish

Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.

Abstracts

-TextCopyright
*

BACKGROUND: Radiotherapy combined with androgen-deprivation therapy (ADT) is superior to radiotherapy alone in localised prostate cancer; however, data comparing ADT alone are somewhat limited. OBJECTIVE: To compare 3-yr ADT plus radiotherapy with ADT alone in locally advanced prostate cancer patients. DESIGN, SETTING, AND PARTICIPANTS: A multicentre randomised open controlled phase 3 trial in 264 histologically confirmed T3-4 or pT3N0M0 prostate cancer patients randomised from March 2000 to December 2003. INTERVENTION: ADT (11.25mg subcutaneous depot injection of leuprorelin every 3 mo for 3 yr) plus external-beam radiotherapy or ADT alone. Flutamide (750 g/d) was administered for 1 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary objective was 5 yr progression-free survival (PFS) according to clinical or biologic criteria, using the American Society for Therapeutic Radiology and Oncology (ASTRO) and the newer (Phoenix) definition (nadir plus 2 ng/ml), by intention to treat. Secondary objectives included time to locoregional recurrence and distant metastases, and overall and disease-specific survival. Our Analyses: intent-to-treat analysis, multivariate analyses using a Cox model with a 5% threshold from univariate analysis, and Kaplan-Meier estimates. RESULTS AND LIMITATIONS: ADT alone was administered to 130 patients and combined therapy to 133. With a median follow-up of 67 mo, 5-yr PFS was 60.9% for combined therapy versus 8.5% with ADT alone (ASTRO; p<0.0001), and 64.7% versus 15.4%, respectively, for Phoenix (p<0.0011). Locoregional progression was reported in 9.8% of combined-therapy patients versus 29.2% with ADT alone (p<0.0001) and metastatic progression in 3.0% versus 10.8%, respectively (p<0.018). Overall survival was 71.4% with combined therapy versus 71.5% with ADT alone; disease-specific survival was 93.2% versus 86.2%. Limitations included the relatively small population and a relatively short follow-up period. CONCLUSIONS: Combined therapy strongly favoured improved PFS, locoregional control, and metastasis-free survival. Longer follow-up is needed to assess the potential survival impact.

Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

relatesTo

type: comment-in

classifier: Comment

citation:

Eur Urol. 2012 Aug;62(2):220-1; author reply 222-3. doi: 10.1016/j.eururo.2012.04.040

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/22552217/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22552217

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1873-7560, ISOAbbreviation/Eur Urol, ISSN Linking/0302-2838, Medline Title Abbreviation/Eur Urol, NLM Unique ID/7512719

title: European urology

publisherLocation: Switzerland

citedMedium: Internet

volume: 62

issue: 2

articleDate: 2012-08

publicationDateText: 2012-Aug

language: English

pageString: 213-9

publicationForm

citedMedium: Internet without issue

articleDate: 2012-04-03

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/22502942/

webLocation

classifier: DOI Based

url: https://doi.org/10.1016/j.eururo.2012.03.053

classification

type: Publishing Model

classifier: Print Electronic

classification

type: Chemical

classifier: Androgen Antagonists, Antineoplastic Agents, Hormonal, Flutamide, Prostate-Specific Antigen, Leuprolide

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Mottet N

forenameInitials: N

affiliation: Department of Urology, University Hospital, St. Etienne, France. nicolas.mottet@wanadoo.fr

entry

contributor: Peneau M

forenameInitials: M

entry

contributor: Mazeron JJ

forenameInitials: JJ

entry

contributor: Molinie V

forenameInitials: V

entry

contributor: Richaud P

forenameInitials: P

Generated Narrative: Practitioner #contributor0

name: Nicolas Mottet

Generated Narrative: Practitioner #contributor1

name: Michel Peneau

Generated Narrative: Practitioner #contributor2

name: Jean-Jacques Mazeron

Generated Narrative: Practitioner #contributor3

name: Vincent Molinie

Generated Narrative: Practitioner #contributor4

name: Pierre Richaud

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.

content

type: components (if present) include qualifier codings

classifier: Adenocarcinoma

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: radiotherapy

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapy

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Aged

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Androgen Antagonists

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Antineoplastic Agents, Hormonal

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Chemoradiotherapy

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Disease-Free Survival

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Drug Therapy, Combination

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Flutamide

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Leuprolide

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Middle Aged

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Neoplasm Grading

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Prostate-Specific Antigen

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: blood

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Prostatic Neoplasms

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: radiotherapy

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapy

Components

-TypeClassifier
*is Major topicYes